AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
15.7.2025 09:50:00 CEST | ACCESS Newswire | Press Release
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin
Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action
VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).
Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system.
"With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis."
"We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step."
"We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area."
AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.
About AATec Medical
AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow AATec on LinkedIn.
About Northway Biotech
Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit https://www.northwaybiotech.com.
Northway Biotech Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
AATec Medical Contact:
Dr. Rüdiger Jankowsky, CEO
info@aatec-medical.com
Media Contact:
MC Services
Katja Arnold, Julia von Hummel
aatec-medical@mc-services.eu
Phone: +49 (0)89 2102280
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production23.10.2026 18:00:00 CEST | Press Release
SAN DIEGO, CA / ACCESS Newswire / October 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in Uncrewed Aircraft Systems (UAS), today is announcing our partnership with Spirit Defense, a Boeing Company, to support airframe production of the new FQ-42 Vengeance Collaborative Combat Aircraft (CCA). In June, GA-ASI won a contract from the U.S. Air Force (USAF) to produce FQ-42. Spirit Defense's role as a fuselage design-build partner brings together the company's engineering and advanced manufacturing capabilities to support the program from design through production. GA-ASI has been the sole manufacturer of its line of UAS - which includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian - since the company's inception in 1992. For the FQ-42 program, partnering with Spirit Defense is a strength multiplier for the company and the nation, offering manufacturing capacity and industrial depth to scale CCA production faster, w
Study Finds Lower Rates of Overweight Among Vegan-Fed Cats23.10.2026 16:45:00 CEST | Press Release
LONDON, UK / ACCESS Newswire / October 23, 2026 / A large-scale survey published in Frontiers in Animal Science has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets. An online survey analysed carer-reported veterinary assessments of 1,305 cats fed either conventional meat-based (90%) or vegan (10%) diets for at least one year. After accounting for factors including age, sex, neuter status, activity and feeding practices, vegan-fed cats had 34% lower odds of being assessed as overweight. However, the difference was not statistically significant, in part reflecting the relatively small number of vegan-fed cats. For several body weight-related problems, no vegan-fed cats were affected. Nevertheless, researchers say the findings show an interesting trend that warrants further investigation. Overweight and obesity are common in domestic cats, with veterinary studies estimating that around 30-60% of cats are overw
Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award23.10.2026 16:00:00 CEST | Press Release
SHANGHAI, CHINA / ACCESS Newswire / October 23, 2026 / Leggett Dynamics today announced that its Mid-Class Massage System (MCM) received Gasgoo's Best Technical Practice Award during a ceremony held at the 14th annual Automotive & Environment Innovation Forum in Shanghai. The Gasgoo Best Technical Practice Award honors automotive technologies that have proven innovation, production readiness and measurable customer value in real-world vehicle applications. The judging panel cited MCM's innovation that achieves affordable, premium-level comfort for mid-class vehicle programs. About Leggett Dynamics' Mid-Class Massage System Leggett Dynamics' MCM is a comfort innovation that expands premium massage technology beyond the luxury vehicle segment. Already in serial production with a leading global OEM and generating strong interest from multiple global automakers, the innovation delivers a premium massage experience while reducing system cost and complexity through the intelligent use of pre
New Global Initiative Seeks to Modernize Health Workforce Mobility22.10.2026 17:00:00 CEST | Press Release
PHILADELPHIA, PA, TORONTO, ON AND GRONINGEN, NETHERLANDS / ACCESS Newswire / October 22, 2026 / TruMerit® and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. The initiative is detailed in a newly published paper titled "Toward a Global Digital Credential Mobility Ecosystem for Migrating Health Professionals." As healthcare systems worldwide face persistent workforce shortages, internationally educated health professionals often encounter lengthy, duplicative, and inconsistent credential recognition processes that can delay entry into practice. The paper proposes a new approach centered on a Global Competency Record (GCR). This portable digital record could securely bring together verified evidence of a professional's educ
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards22.10.2026 15:00:00 CEST | Press Release
ANTWERPEN, BE / ACCESS Newswire / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation.Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, plann
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom